Results of the first study ever to assess efficacy across all symptoms commonly experienced during a migraine attack found that treatment with ZOMIG(R) (zolmitriptan) Nasal Spray produced a significantly higher rate of total symptom relief, defined as freedom from pain, nausea, and sensitivity to light and sound, at one hour after the first dose compared to placebo.(1) The study, published this month in the American Headache Society's peer-reviewed journal Headache, examined patients in a setting closely resembling normal clinical practice where patients were free to treat an attack of any baseline intensity and at any time after onset.

"This is the first migraine study ever to look at total symptom relief at one hour compared to placebo," said Marek Gawel, MB BCh, FRCPC, consulting neurologist, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada and lead investigator of the REALIZE (Real Life Intranasal Zolmitriptan Exposure) study. "Historically, migraine studies have looked only at reducing headache pain and not the range of equally debilitating symptoms that can disrupt daily life activities."

The total symptom relief rate one hour postdose was significantly higher in patients using ZOMIG Nasal Spray than those using placebo (14.5% vs 5.1%; P The headache response rate with ZOMIG Nasal Spray reached a value of 64.8% by two hours postdose vs 23.9% for placebo (P